Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Genital Herpes01:23

Genital Herpes

Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reviving grain quality in wheat through non-destructive phenotyping techniques like hyperspectral imaging.

Food and energy security·2024
Same author

Effect of Salt Addition and Fermentation Time on Phenolics, Microbial Dynamics, Volatile Organic Compounds, and Sensory Properties of the PDO Table Olives of Gaeta (Italy).

Molecules (Basel, Switzerland)·2022
Same author

A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.

BMC infectious diseases·2022
Same author

Prediction of coffee aroma from single roasted coffee beans by hyperspectral imaging.

Food chemistry·2021
Same author

Use of Meat-Bone Paste to Develop Calcium-Enriched Liver Pâté.

Foods (Basel, Switzerland)·2021
Same author

Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.

Journal of hepatology·2021

Related Experiment Video

Updated: Jun 5, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

HBV therapy: guidelines and open issues.

Alfredo Alberti1, Nicola Caporaso

  • 1Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Italy. alfredo.alberti@unipd.it

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|January 4, 2011
PubMed
Summary
This summary is machine-generated.

Chronic hepatitis B treatment involves finite interferon therapy or indefinite nucleoside/nucleotide analogue (NUC) therapy. This review focuses on recent guidelines, including the 2010 Italian recommendations for managing chronic hepatitis B infection.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Current chronic hepatitis B treatment strategies include finite pegylated interferon therapy aiming for sustained virological response and indefinite oral nucleoside/nucleotide analogue (NUC) therapy for viral suppression.
  • Pegylated interferon is most effective in patients with less advanced liver disease, high ALT, low HBV-DNA, and specific genotypes (A or B).
  • NUC therapy is typically reserved for patients with advanced liver disease or those who cannot tolerate interferon.

Purpose of the Study:

  • To summarize recent recommendations for chronic hepatitis B treatment.
  • To highlight the evolving role of third-generation NUCs in hepatitis B management.
  • To provide a specific focus on the 2010 Italian Guidelines for chronic hepatitis B infection.

Main Methods:

  • Review of recent clinical guidelines and recommendations for chronic hepatitis B treatment.
  • Analysis of treatment strategies, including pegylated interferon and oral NUCs.
  • Focus on the 2010 Italian Guidelines and their implications.

Main Results:

  • Pegylated interferon therapy offers a finite treatment course with potential for long-term response.
  • Indefinite NUC therapy aims for complete and sustained suppression of HBV replication.
  • Third-generation NUCs have increased the credibility and indications for oral therapy, though guidelines often restrict their use to advanced liver disease.

Conclusions:

  • Treatment decisions for chronic hepatitis B depend on disease stage, patient factors, and treatment history.
  • The advent of potent NUCs is shifting treatment paradigms, necessitating updated guideline considerations.
  • The 2010 Italian Guidelines provide a framework for managing chronic hepatitis B, emphasizing a tailored approach to therapy.